| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
The primary target of MPI-5a is histone deacetylase 6 (HDAC6). It is a highly selective HDAC6 inhibitor with an IC₅₀ of 36 nM. MPI-5a has weak inhibitory activity against other HDAC isoforms. By inhibiting HDAC6, it affects the deacetylation of α-tubulin and other HDAC6 substrates.
|
|---|---|
| ln Vitro |
In vitro, MPI-5a potently inhibits HDAC6 enzymatic activity with an IC₅₀ of 36 nM. It inhibits the accumulation of intracellular acyl-tubulin with an IC₅₀ of 210 nM. The compound shows weak activity against other HDAC enzymes, demonstrating high selectivity for HDAC6.
|
| ln Vivo |
In vivo efficacy of MPI-5a has been studied in animal models. As a selective HDAC6 inhibitor, it modulates tubulin acetylation and affects cellular processes such as protein degradation and cell motility. Detailed in vivo data including dosing regimens and efficacy endpoints are available from preclinical studies.
|
| Enzyme Assay |
For in vitro enzyme assays, MPI-5a is tested against HDAC6 and other HDAC isoforms. Standard protocols involve incubating the enzyme with a fluorogenic substrate and varying concentrations of MPI-5a (0.1-1000 nM). Fluorescence is measured to determine enzymatic activity. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays for MPI-5a involve treating cells (e.g., cancer cell lines) with the compound at concentrations of 0.01-10 µM for 24-72 hours. Inhibition of HDAC6 activity is assessed by measuring acetyl-tubulin levels via Western blot. Cell viability is measured by MTT assays. Selectivity is confirmed by assessing other HDAC substrates.
|
| Animal Protocol |
In vivo studies with MPI-5a are conducted in rodent models. Typical protocols involve administering the compound orally or intraperitoneally at doses of 1-50 mg/kg. Efficacy is assessed by measuring biomarker changes (e.g., acetyl-tubulin levels in tissues) and disease endpoints depending on the model. Pharmacokinetic parameters are determined from plasma samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MPI-5a have been characterized in preclinical studies. The compound is likely orally bioavailable. It distributes to tissues where HDAC6 is expressed. Metabolism occurs via hepatic pathways. Detailed PK parameters including half-life, Cmax, and AUC are available from research publications.
|
| Toxicity/Toxicokinetics |
Toxicology data for MPI-5a are available from preclinical safety studies. As a selective HDAC6 inhibitor, it is generally well-tolerated at therapeutic doses. HDAC6 inhibition is associated with manageable toxicity profiles. Comprehensive toxicology data can be found in research publications.
|
| References | |
| Additional Infomation |
MPI-5a is a potent and selective HDAC6 inhibitor used in epigenetics research. It is also known as N-hydroxy-2-(1-methyl-1H-pyrrole-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide. It is useful for studying the role of HDAC6 in cancer, neurodegeneration, and other diseases. No clinical trials or FDA approvals exist.
|
| Molecular Formula |
C16H17N3O3
|
|---|---|
| Molecular Weight |
299.33
|
| Exact Mass |
299.126
|
| Elemental Analysis |
C, 64.20; H, 5.72; N, 14.04; O, 16.03
|
| CAS # |
1259296-46-2
|
| Related CAS # |
1259296-46-2
|
| PubChem CID |
49831258
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.660
|
| LogP |
-1.01
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
442
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C2=C(C=C(C(NO)=O)C=C2)CCN1C(C1=CC=CN1C)=O
|
| InChi Key |
NNQAQGDSGCGFER-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H17N3O3/c1-18-7-2-3-14(18)16(21)19-8-6-11-9-12(15(20)17-22)4-5-13(11)10-19/h2-5,7,9,22H,6,8,10H2,1H3,(H,17,20)
|
| Chemical Name |
N-hydroxy-2-(1-methylpyrrole-2-carbonyl)-3,4-dihydro-1H-isoquinoline-6-carboxamide
|
| Synonyms |
MPI5a; MPI 5a; MPI-5a
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3408 mL | 16.7040 mL | 33.4079 mL | |
| 5 mM | 0.6682 mL | 3.3408 mL | 6.6816 mL | |
| 10 mM | 0.3341 mL | 1.6704 mL | 3.3408 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
